Pharmacological activity of new imidazole-4,5-dicarboxylic acid derivatives in dopaminergic transmission suppression ttests in mice and rats

Authors

DOI:

https://doi.org/10.3897/rrpharmacology.6.57883

Abstract

Objective: To study the antiparkinsonian activity of new 1,2-substituted imidazole-4,5-dicarboxylic acids in dopami­nergic transmission suppression tests in mice and rats.

Materials and methods: On a model of reserpine extrapyramidal disorders, the derivatives of imidazole-dicarboxylic acids (IEM2258, IEM2248, IEM2247) were injected into the lateral brain ventricles of the mice 30 minutes after inject­ing reserpine at the doses of 0.1–0.5 mmol. Locomotor activity was analyzed in the Open-field test 2 hours later. In the catalepsy model, the studied agents were injected, using a pre-implanted cannula, with a simultaneous intraperitoneal injection of haloperidol. The severity of catalepsy was assessed with the Morpurgo method. Amantadine was used as a comparator drug in all the tests.

Results: It was shown that IEM2258 significantly increased the main indicators of locomotor activity in the Open-field test at all the studied doses. The value of the antiparkinsonian effect of IEM2258 at doses of 0.4–0.5 mmol significantly exceeded that of amantadine. The antiparkinsonian effect of IEM2247 was maximally expressed and was significantly different from those in the control and comparator group at doses of 0.2 and 0.3 mmol. For all the experimental groups, a significant decrease in the manifestations of catalepsy in comparison with control indexes was determined.

Discussion: The results made it possible to suggest the involvement of imidazole-4,5-dicarboxylic acids derivatives in the process of experimental improvement of dopaminergic neuromodulation and efficiency in animals.

Conclusion: The data showed a significant dose-dependent antiparkinsonian activity of new imidazole-4,5-dicarbox­ylic acid derivatives, which makes it promising to develop these agents and to further search for effective and safe antiparkinsonian drugs in this pharmacological class.

Graphical abstract:

Keywords:

Parkinson’s disease, glutamate, NMDA-receptor antagonists, imidazole-dicarboxylic acid derivatives, antiparkinsonian activity

Author Contribution

Ekaterina E. Yakovleva, Institute of Experimental Medicine

PhD in Medicine, research fellow of The Laboratory of Chemistry and Pharmacology of Drugs, Department of Neuropharmacology.

Eugeny R. Bychkov, Institute of Experimental Medicine

PhD in Medicine Head of The Laboratory of Chemistry and Pharmacology of Drugs, Department of Neuropharmacology.

Maria A. Brusina, Institute of Experimental Medicine

PhD in Chemistry, junior research fellow of The Laboratory for the Synthesis and Nanotechnology of Drugs, Department of Neuropharmacology.

Levon B. Piotrovsky, Institute of Experimental Medicine

Doctor Habil.of Biological Sciences, Head of The Laboratory for the Synthesis and Nanotechnology of Drugs, Department of Neuropharmacology.

Petr D. Shabanov, Institute of Experimental Medicine; Kirov Military Medical Academy

Doctor Habil. of. Medicine, Professor, Head of Department of Neuropharmacology; Head of Department of Pharmacology.

Downloads

Published

07-12-2020

How to Cite

Yakovleva EE, Bychkov ER, Brusina MA, Piotrovsky LB, Shabanov PD (2020) Pharmacological activity of new imidazole-4,5-dicarboxylic acid derivatives in dopaminergic transmission suppression ttests in mice and rats. Research Results in Pharmacology 6(4): 51–57. https://doi.org/10.3897/rrpharmacology.6.57883

Issue

Section

Review article